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Case Report
Introduction
According to the World Health Organization classification 
of 2008,1 mantle cell lymphoma (MCL) is classified as a 
mature B-cell lymphoma, comprising about 6% of all adult 
non-Hodgkin’s lymphoma (NHL) in the United States. MCL 
is aggressive and usually diagnosed at an advanced stage of 
the disease in middle-aged to older patients. Its incidence has 
risen over recent years and is noted to be highest among 
males, Caucasians, and older patients (median age 67 years 
at diagnosis).2
Although an increased long-term risk for developing 
secondary neoplasms, including lung cancer, has also been 
described among NHL survivors,3,4 a histopathological diag-
nosis of 2 synchronous malignancies at the same site is 
exceedingly rare. In this article, we present the case of a 
middle-aged female diagnosed with MCL and primary pul-
monary adenocarcinoma within the same nodule.
Case Report
A 55-year-old female presented to the emergency depart-
ment for evaluation of severe lower flank pain radiating to 
her lower abdomen and chest. Further review of symptoms 
revealed that she also had cough, night sweats, chills, and 
an unintentional weight loss of 31 pounds over 3 months. 
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Abstract
Introduction. Mantle cell lymphoma (MCL) comprises approximately 3% to 10% of all non-Hodgkin lymphomas. Although 
there is an increased risk for secondary malignancies after treatment among non-Hodgkin lymphomas survivors, a 
synchronous diagnosis of primary lung cancer arising in conjunction with lymphoma at the same site has rarely been 
reported. We report an unusual case of primary lung adenocarcinoma with coexistent MCL within the same lung 
lesion. Case Presentation. A 55-year-old female with newly diagnosed stage IV-B MCL was referred for workup of a 
right upper lobe cavitary lesion detected during lymphoma staging. A whole-body positron-emission tomography-
computed tomography scan revealed diffuse adenopathy but also identified a cavitary right upper lobe lesion atypical 
for lymphoma. Bronchoscopy was unremarkable with cytology (on lavage) negative for malignancy. At 2 months, a 
computed tomography scan of the chest showed a persistent lesion. A video-assisted thoracoscopic wedge resection 
was performed. Histopathological examination revealed a lepidic predominant, well-differentiated adenocarcinoma 
(stage T1a) and foci of lymphoid infiltrate within and adjacent to the adenocarcinoma consistent with lung involvement 
by MCL. Discussion. Synchronous presentation of primary lung adenocarcinoma and lymphoma at a single site is 
exceedingly rare. Nonresolving pulmonary lesions with features atypical for lymphoma should be viewed with caution 
and worked up comprehensively to rule out occult second malignancies, in order to guide a prompt diagnosis and 
appropriate treatment.
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Clinical examination was significant for bilateral axillary 
lymphadenopathy. Subsequently, a computed tomography 
(CT) scan of her chest, abdomen, and pelvis was performed 
that revealed extensive bilateral lymphadenopathy (above 
and below the diaphragm) as well as a new right upper lobe 
(RUL) thin-walled cavitary lung lesion with spiculated 
margins (Figure 1a). A positron-emission tomography (PET)- 
CT scan showed highly metabolically active lymphadenop-
athy in the neck, chest, abdomen, and pelvis but minimal to 
no PET avidity within the RUL cavitary lesion (Figure 1b). 
Axillary lymph node sampling showed moderate-to-large 
B-lymphocytes (positive for CD5, CD20, and cyclin D1), 
with fluorescence in situ hybridization positive for t(11; 
14), consistent with MCL. Although a bone marrow biopsy 
revealed low disease burden (<10% involvement), her 
lymphoma demonstrated a high proliferation rate (Ki67 
proliferation index 30%), and she was diagnosed with stage 
IV-B MCL.
Prior to initiation of chemotherapy, she was referred to the 
pulmonary clinic for workup of the lung lesion, which was 
felt to have radiographic features atypical for lymphoma. 
She was an active, 30 pack-year smoker with symptoms of 
stable chronic bronchitis, sinusitis, and scant hemoptysis. 
Serum tuberculosis testing (TB-quantiferon) was negative. 
Although no prior self-history of cancer, she had a strong 
family history for cancer (lung cancer [father, paternal uncle, 
and paternal grandfather], cervical cancer [mother], and pre-
menopausal breast cancer [paternal aunt]). Chest CT was sig-
nificant for severe emphysema, multiple indeterminate 
pulmonary nodules, and a 1.7 × 1.1 cm, subpleural, thin-walled 
Figure 1. (a) Computed tomography scan of chest showing a 1.7 × 1.1 cm right upper lobe cavitary nodule. (b) Positron-emission 
tomography scan showing extensive lymphadenopathy both above and below the diaphragm but no uptake in the right upper lobe 
cavitary lesion.
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cavitary lesion with spiculated margins in the RUL (Figure 1a). 
Initial differential diagnosis included malignancy (primary/
metastatic carcinoma and less likely lymphoma), subacute or 
chronic infections (such as tuberculosis and fungal infec-
tion), and vasculitis. Bronchoscopy was unremarkable, and 
bronchoalveolar lavage showed 87% macrophages, 10% 
neutrophils, and 2% lymphocytes, without malignant cells. 
Respiratory cultures grew 1+ Aspergillus flavus. Serum anti-
neutrophil cytoplasmic antibodies and rheumatoid arthritis 
factor were negative. A short-interval (2 months) follow-up 
CT imaging showed stable pulmonary nodules but a persistent 
RUL cavitary lesion. A video-assisted thoracoscopic wedge 
resection was performed to exclude other diagnoses prior to 
initiation of chemotherapy for MCL. Pathological examina-
tion revealed a lepidic predominant, well-differentiated ade-
nocarcinoma (pathological stage T1a), with coexistent foci of 
lymphoid infiltrates within and adjacent to adenocarcinoma 
(Figure 2a). The lymphoid infiltrate had histological fea-
tures (convoluted irregular small nuclei; Figure 2b). By 
immunohistochemistry, the adenocarcinoma component was 
strongly positive with thyroid transcription factor-1, con-
firming pulmonary origin (Figure 2c) and discounting the 
possibility of metastasis from a possible mammary carci-
noma. In addition, immunohistochemical profile (positive for 
B-cell markers CD20, pax5, and BCL1 [cyclin D1]; Figure 3a 
and b) was consistent with MCL. Multidisciplinary consensus 
was that no additional surgery, lymph node sampling, or adju-
vant chemotherapy was needed. She was subsequently 
observed for both adenocarcinoma and lymphoma (high pro-
liferation rate but with low disease burden), with surveil-
lance imaging. A year later, however, she presented with 
dyspnea and a new right-sided pleural effusion (cytology 
positive for adenocarcinoma, negative for epithelial growth 
factor receptor/anaplastic lymphoma kinase). She received 6 
cycles of carboplatin/pemetrexed/bevacizumab with good 
treatment response; however, she declined further mainte-
nance therapy due to an intolerance of side effects. A few 
months later (a year ago), she presented with weight loss, 
chills, and night sweats, and CT imaging showed progressive 
lymphadenopathy concerning for MCL. She received ibruti-
nib and rituximab with good response initially; however, she 
could not complete the prescribed therapy due to side effects 
and was unfortunately lost to follow-up at the time of this 
writing.
Figure 2. (a) Histopathological examination revealed an infiltrating lepidic predominant adenocarcinoma (white arrow) with coexistent 
foci of lymphoid infiltrate (black arrow). (b) High-power examination revealed small, irregular, convoluted lymphocytes comprising the 
lymphoid infiltrate (black arrow). Adenocarcinoma cells (white arrow) show atypical, large nuclei with prominent nucleoli (hematoxylin 
and eosin). (c) Immunohistochemistry showing strong positivity for thyroid transcription factor-1.
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Figure 3. Immunohistochemistry revealed lymphocytes showing strong and diffuse positivity for (a) generic B-cell marker CD20 and (b) 
mantle cell lymphoma (MCL) marker cyclin D1.
Discussion
Our case highlights 2 important findings. First, this is a very 
rare case of synchronous primary lung cancer and MCL 
found within the same cavitary lung nodule. Second, this 
case highlights important features of lung lesions/nodules 
that would be considered “unusual or atypical” for lympho-
matous involvement of the lung and raise concern for a pos-
sible secondary process in the lung.
Large population-based cancer registry reviews show 
that NHL survivors are at a significantly greater risk for sec-
ondary malignancies than the normal population (all solid 
tumors; observed to expected ratio = 1.37).3 This risk 
remains elevated even up to 30 years after treatment for 
NHL and is independent of the use of external beam radia-
tion therapy.4 Lymphomas and leukemias tend to be among 
the most common neoplasms involved even as subsequent 
neoplasms, and usually arise within the first 5 years.5 Solid 
tumors are more common after 5 years, with breast and lung 
cancer being the most frequent.6 In a review of 77 823 
patients, Tward et al demonstrated that NHL survivors have 
an absolute excess cancer risk of 6.36 times (in men) and 
7.10 times (in women) for a second primary lung and/or 
mediastinal tumor, specifically.4
Despite these increased risks, however, a diagnosis of a 
synchronous second malignancy with a coexistent lymphop-
roliferative disorder is still quite rare. Synchronous multiple 
primary cancers are defined as 2 or more primary tumors 
occurring within 6 months of each other.7,8 In reviewing the 
medical literature, it appears that an association between 
NHL and breast cancer is well recognized. Wiernik et al, in a 
large series of 87 cases, established that in women with both 
breast cancer and NHL, lymphoma is significantly more likely 
to be diagnosed after or concurrently with breast cancer. The 2 
malignancies could be seen in separate organs, or as “collision 
tumors,” with coexistence in anatomic proximity to each 
other.9 Experimental evidence also appears to suggest that 
breast cancer and lymphoma of the breast may share some 
common biologic characteristics.10 However, we found only 
a handful of case reports that document synchronous NHL 
and primary lung cancer.11-13 Within NHL, MCL appears to 
be more commonly associated with secondary genitourinary 
malignancies rather than lung cancer.14 Where authors report 
synchronous MCL and primary lung cancer, it is either at 
separate sites15 or in the form of metastases to the same 
regional lymph node.16 We found only 2 reports describing 
synchronous involvement of same thoracic site (ie, pleura) 
by both MCL and primary lung cancer17,18 (summarized in 
Table 1). Our case adds itself to a rare but growing list of 
reports of synchronous MCL and primary lung cancer, and is 
also the first, to our knowledge, to report synchronous MCL 
and primary lung cancer within the same cavitary lung nod-
ule (“collision histology”).
The biological mechanisms behind the pathogenesis of 
such synchronous multiple primary malignancies are still 
largely unknown. Authors have proposed certain mechanisms 
such as the possible spread of cancerous cells from a single 
clone to multiple sites,19 genetic defects involving mismatch 
repair systems,20 a positive family history of malignancy,8 
and/or a complex interplay of genetics, impaired immunity, 
viremia (ie, Epstein-Barr virus, etc), and carcinogenic risk 
factors (such as smoking) that ultimately all contribute to the 
development of synchronous multiple primary cancers.5 It is 
plausible that both complex genetics and history of smoking 
placed our patient at risk for these 2 tumors.
Second, this case highlights some important diagnostic 
and radiological considerations. It is conceivable that the 
detection of a second pulmonary malignancy was simply an 
incidental finding in our patient (a smoker) and that a lym-
phoma staging workup essentially replaced what could 
have been routine age-appropriate lung cancer screening 
otherwise (our center sees about 2 to 3 such cases annually 
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Table 1. Case Reports Citing Synchronous Occurrence of Non-Hodgkin’s Lymphoma and Primary Lung Cancer.
Title Authors Year Site Case Description
Coexistence of non-Hodgkin’s 
lymphoma and non–small-cell 
lung carcinoma: diagnosis and 
treatment
Rothenburger 
et al11
2001 Different sites; 
lung mass and 
lymph nodes
A 67-year-old NHL survivor developed new diffuse 
lymphadenopathy and a pulmonary mass. Inguinal lymph 
node biopsy revealed relapsed NHL. Due to lack of 
treatment response seen in the pulmonary mass, a 
complex lobectomy was performed and revealed a 
secondary non–small-cell lung cancer.
Synchronous pulmonary 
adenocarcinoma and extranodal 
marginal zone/low-grade B-cell 
lymphoma of the MALT type
Chanel et al12 2001 Same site 
(pulmonary 
mass)
An interesting case of a 74-year-old male with a 
nonresolving pulmonary mass that was surgically 
removed to reveal synchronous adenocarcinoma and 
extranodal low-grade B-cell lymphoma of the MALT type.
Mantle cell lymphoma in lymph 
nodes with metastatic small cell 
carcinoma of lung: a diagnostic 
and treatment dilemma
Kampalath 
et al16
2004 Same site 
(lymph nodes)
A 58-year-old female with metastatic small cell lung cancer 
with synchronous mantle cell lymphoma.
A rare tumoral combination, 
synchronous lung 
adenocarcinoma and mantle cell 
lymphoma of the pleura
Hatzibougias 
et al18
2008 Same site 
(pleura)
A 73-year-old male who underwent a bullectomy for 
persistent pneumothorax was incidentally diagnosed 
with synchronous pulmonary adenocarcinoma and MCL 
of the pleura.
Synchronous pulmonary 
squamous cell carcinoma and 
mantle cell lymphoma of the 
lymph node
Sun et al15 2011 Different sites; 
lung mass and 
lymph nodes
A 57-year-old male presenting with a right lower 
lobe pulmonary mass and cervical and mediastinal 
lymphadenopathy. The lung mass was biopsied to show 
squamous cell lung cancer and the lymphadenopathy 
revealed MCL.
Synchronous BALT lymphoma 
and squamous cell carcinoma 
of the lung: coincidence or 
linkage?
Oikonomou 
et al13
2013 Different sites; 
2 nodules 
in separate 
lobes
A 72-year-old male presents with 2 large masses (one in 
the right middle lobe and another in left lower lobe). 
Biopsy of the left lobe revealed a BALT lymphoma. 
When the right mass did not respond to lymphoma 
therapy, a second biopsy was done and revealed 
concomitant squamous cell lung cancer.
Synchronous pulmonary 
malignancies: atypical 
presentation of mantle cell 
lymphoma masking a lung 
malignancy
Masha et al17 2015 Same site 
(pleura)
A 70-year-old male presented with a large right pleural 
effusion. Pleural fluid analysis clonal populations 
consistent with mantle cell lymphoma. He underwent 
treatment for lymphoma with no improvement. A 
CT-guided biopsy then revealed tissue consistent with 
undifferentiated carcinoma, favoring lung primary.
Abbreviations: NHL, non-Hodgkin’s lymphoma; MALT, mucosa-associated lymphoid tissue; MCL, mantle cell lymphoma; BALT, bronchus-associated 
lymphoid tissue; CT, computed tomography.
[personal communication]). However, this case emphasizes 
that it is also important to be cognizant of the “usual” or 
“typical” patterns of lung involvement with lymphoma. 
Extranodal thoracic involvement is not uncommon with 
NHL and may represent either primary pulmonary lym-
phoma or secondary spread. Common radiographic patterns 
of lymphomatous pulmonary involvement include diffuse 
interstitial thickening, mass-like consolidation with homog-
enous attenuation, air-bronchograms and preserved vascular 
markings, perilymphatic nodularity, and PET avidity in the 
lung similar to other known sites involved with NHL.21 This 
lesion was atypical given its isolated, peripheral, “cavitary” 
nature and without any significant PET avidity in compari-
son with surrounding lymphadenopathy (Figure 1b). Instead, 
an extensive smoking history coupled with radiographic 
findings of a single cavitary lesion with spiculated margins, 
measuring more than 10 mm in size, made her odds of 
having a potential secondary process such as a lung malig-
nancy much more likely.
It is also important to note an “unresolving” nature of cer-
tain pulmonary lesions/nodules. In several prior published 
reports, we observe that an initial diagnosis is often reached 
via a biopsy of a certain site. However, it is the “unresolving” 
nature or “lack of a complete response” to appropriate ther-
apy that often prompts physicians to search for an alternate 
or synchronous diagnosis.11-13,17
In summary, we describe here a very unusual case of 
MCL and primary pulmonary adenocarcinoma presenting 
synchronously within one cavitary lung lesion. Synchronous 
malignancies such as these are exceedingly rare and crucial 
to identify promptly as treatment can be markedly different. 
This case highlights the importance of a high index of clini-
cal suspicion of lesions that do not resolve on short-term 
follow-up (either spontaneously or with treatment) and a 
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keen radiologic awareness of the features that would be 
unusual for lymphomatous involvement of the lung.
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